Niacin sensitivity and the arachidonic acid pathway in schizophrenia

Schizophrenia Research

Volumn 122, Issue 1-3, 2010, Pages 248-256

  Messamore, Erik ^a   Hoffman, William F ^a   Yao, Jeffrey K ^b,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenic acid; Arachidonic acid; Niacin; RBC membrane; Schizophrenia

Indexed keywords

ADRENIC ACID; ARACHIDONIC ACID; DIHOMO GAMMA LINOLENIC ACID; LINOLENIC ACID; NEUROLEPTIC AGENT; NICOTINIC ACID METHYL ESTER; OMEGA 6 FATTY ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE MEMBRANE; FATTY ACID ANALYSIS; FEMALE; FLUSHING; FOREARM; GAS CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SKIN BLOOD FLOW;

ADULT; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; ERUCIC ACIDS; FATTY ACIDS, OMEGA-6; FEMALE; FLUSHING; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NIACIN; NICOTINIC ACIDS; REGRESSION ANALYSIS; SCHIZOPHRENIA; SKIN; SKIN TESTS;

EID: 77956190705     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.03.025     Document Type: Article

References (42)

1. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., Bennett C., Ranjekar P.K., Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 2003, 53(1):56-64.
2. Benyo Z., Gille A., Kero J., Csiky M., Suchankova M.C., Nusing R.M., Moers A., Pfeffer K., Offermanns S. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J. Clin. Invest. 2005, 115(12):3634-3640.
3. Benyo Z., Gille A., Bennett C.L., Clausen B.E., Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol. Pharmacol. 2006, 70(6):1844-1849.
4. Bosveld-van Haandel L., Knegtering R., van den Kluiter H., Bosch R.J. Niacin skin flushing in schizophrenic and depressed patients and healthy controls. Psychiatry Res. 2006, 143(2-3):303-306.
5. Chang S.S., Liu C.M., Lin S.H., Hwu H.G., Hwang T.J., Liu S.K., Hsieh M.H., Guo S.C., Chen W.J. Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading. Schizophr. Bull. 2009, 35(1):213-221.
6. Das I., Khan N.S. Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglandins Leukot. Essent. Fatty Acids 1998, 58(3):165-168.
7. Dodge J.T., Mitchell C., Hanahan D.J. The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. Arch. Biochem. Biophys. 1963, 100:119-130.
8. Eklund B., Kaijser L., Nowak J., Wennmalm A. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 1979, 17(6):821-830.
9. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) 1997, American Psychiatric Press, Washington, D.C.
10. Glen A.I., Cooper S.J., Rybakowski J., Vaddadi K., Brayshaw N., Horrobin D.F. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukot. Essent. Fatty Acids 1996, 55(1-2):9-15.
11. Hudson C.J., Lin A., Cogan S., Cashman F., Warsh J.J. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?. Biol. Psychiatry 1997, 41(5):507-513.
12. Hudson C., Gotowiec A., Seeman M., Warsh J., Ross B.M. Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia. Biol. Psychiatry 1999, 46(3):401-405.
13. Ichihara K., Shibahara A., Yamamoto K., Nakayama T. An improved method for rapid analysis of the fatty acids of glycerolipids. Lipids 1996, 31(5):535-539.
14. Krachler B., Norberg M., Eriksson J.W., Hallmans G., Johansson I., Vessby B., Weinehall L., Lindahl B. Fatty acid profile of the erythrocyte membrane preceding development of Type 2 diabetes mellitus. Nutr. Metab. Cardiovasc. Dis. 2008, 18(7):503-510.
15. Lai E., De Lepeleire I., Crumley T.M., Liu F., Wenning L.A., Michiels N., Vets E., O'Neill G., Wagner J.A., Gottesdiener K. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther. 2007, 81(6):849-857.
16. Lin S.H., Liu C.M., Chang S.S., Hwu H.G., Liu S.K., Hwang T.J., Hsieh M.H., Guo S.C., Chen W.J. Familial aggregation in skin flush response to niacin patch among schizophrenic patients and their nonpsychotic relatives. Schizophr. Bull. 2007, 33(1):174-182.
17. Liu C.M., Chang S.S., Liao S.C., Hwang T.J., Shieh M.H., Liu S.K., Chen W.J., Hwu H.G. Absent response to niacin skin patch is specific to schizophrenia and independent of smoking. Psychiatry Res. 2007, 152(2-3):181-187.
18. Maclean R., Ward P.E., Glen I., Roberts S.J., Ross B.M. On the relationship between methylnicotinate-induced skin flush and fatty acids levels in acute psychosis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27(6):927-933.
19. Maida M.E., Hurley S.D., Daeschner J.A., Moore A.H., O'Banion M.K. Cytosolic prostaglandin E2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. Brain Res. 2006, 1103(1):164-172.
20. Messamore E. Relationship between the niacin skin flush response and essential fatty acids in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2003, 69(6):413-419.
21. Messamore E., Hoffman W.F., Janowsky A. The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study. Schizophr. Res. 2003, 62(3):251-258.
22. Miller C.L., Dulay J.R. The high-affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia. Brain Res. Bull. 2008, 77(1):33-41.
23. Morrow J.D., Awad J.A., Oates J.A., Roberts L.J. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest. Dermatol. 1992, 98(5):812-815.
24. Peet M., Shah S., Selvam K., Ramchand C.N. Polyunsaturated fatty acid levels in red cell membranes of unmedicated schizophrenic patients. World J. Biol. Psychiatry 2004, 5(2):92-99.
25. Rey M.J., Schulz P., Costa C., Dick P., Tissot R. Guidelines for the dosage of neuroleptics, 1: chlorpromazine equivalents of orally administered neuroleptics. Int. Clin. Psychopharmacol. 1989, 4(2):95-104.
26. Richardson A.J., Cyhlarova E., Ross M.A. Omega-3 and omega-6 fatty acid concentrations in red blood cell membranes relate to schizotypal traits in healthy adults. Prostaglandins Leukot. Essent. Fatty Acids 2003, 69(6):461-466.
27. Rose H.G., Oklander M. Improved procedure for the extraction of lipids from human erythrocytes. J. Lipid Res. 1965, 6:428-431.
28. Shah S.H., Vankar G.K., Peet M., Ramchand C.N. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophr. Res. 2000, 43(2-3):163-164.
29. Skosnik P.D., Yao J.K. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?. Prostaglandins Leukot. Essent. Fatty Acids 2003, 69(6):367-384.
30. Smesny S., Riemann S., Riehemann S., Bellemann M.E., Sauer H. Quantitative measurement of induced skin reddening using optical reflection spectroscopy - methodology and clinical application. Biomed. Tech. (Berl) 2001, 46(10):280-286.
31. Stern R.H., Spence J.D., Freeman D.J., Parbtani A. Tolerance to nicotinic acid flushing. Clin. Pharmacol. Ther. 1991, 50(1):66-70.
32. Svedmyr N., Heggelund A., Aberg G. Influence of indomethacin on flush induced by nicotinic acid in man. Acta Pharmacol. Toxicol. 1977, 41(4):397-400.
33. Tang Y., Zhou L., Gunnet J.W., Wines P.G., Cryan E.V., Demarest K.T. Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A. Biochem. Biophys. Res. Commun. 2006, 345(1):29-37.
34. Tavares H., Yacubian J., Talib L.L., Barbosa N.R., Gattaz W.F. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr. Res. 2003, 61(1):1-6.
35. Vaddadi K.S., Gilleard C.J., Mindham R.H., Butler R. A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacology (Berl) 1986, 88(3):362-367.
36. Waldo M.C. Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. Schizophr. Res. 1999, 40(1):49-53.
37. Wijendran V., Lawrence P., Diau G.-Y., Boehm G., Nathanielsz P.W., Brenna J.T. Significant utilization of dietary arachidonic acid is for brain adrenic acid in baboon neonates. J. Lipid Res. 2002, 43(5):762-767.
38. Wilkin J.K., Wilkin O., Kapp R., Donachie R., Chernosky M.E., Buckner J. Aspirin blocks nicotinic acid-induced flushing. Clin. Pharmacol. Ther. 1982, 31(4):478-482.
39. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
40. Yao J.K., van Kammen D.P., Welker J.A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 1994, 13(3):217-226.
41. Yao J.K., Dougherty G.G., Reddy R.D., Keshavan M.S., Montrose D.M., Matson W.R., Rozen S., Krishnan R.R., McEvoy J., Kaddurah-Daouk R. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol. Psychiatry 2009, Online publication data: (28 April 2009) doi:10.1038/mp.2009.33.
42. Yao J.K., Dougherty G.G., Reddy R.D., Keshavan M.S., Montrose D.M., Matson W.R., McEvoy J., Kaddurah-Daouk R. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. PLoS One 2010, 5(3):e9508. 10.1371/journal.pone.0009508.